Emergent BioSolutions Inc. Stock Analysis & AI Score
Emergent BioSolutions Inc. (EBS) has an ST Score of 39.5 (C), driven by its Valuation (B) and held back by its Sentiment (F). Analysts rate it Buy with a $10.00 price target (+47.7% upside).
Composite rating from 8 factors. Tap a factor to see the metrics behind its grade.
Company Information
| Employees | — |
| CEO | — |
| Sector | Healthcare |
| Industry | Drug Manufacturers - Specialty & Generic |
| IPO Date | — |
| Website | — |
| Country | — |
| Exchange | NYSE |
SEC Filings
Annual Report (10-K)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
Quarterly Report (10-Q)
| Filing Date | Accepted | Link |
|---|---|---|
| Loading… | ||
ST Score
Emergent BioSolutions Inc. (EBS) has an ST Score of 39.5 (C), driven by its Valuation (B) and held back by its Sentiment (F). Analysts rate it Buy with a $10.00 price target (+47.7% upside).
- Strongest
- ValuationB
- Weakest
- SentimentF
All factor grades
- ValuationB
- ForecastB
- Financial StrengthC+
- GrowthC-
- MomentumD+
- ProfitabilityD
- SentimentF
- Piotroski6/9
Contact
EBS stock: frequently asked questions
What is EBS's ST Score?
Emergent BioSolutions Inc. (EBS) has an ST Score of 39.5 (C), on our 0–100 scale where higher is stronger. The ST Score combines eight factor grades — valuation, profitability, financial strength, momentum, growth, forecast, sentiment and Piotroski — into a single A+ to F rating.
Is EBS a buy, hold, or sell?
Analysts rate EBS a Buy, with a price target of $10.00 (+47.7% vs the current price). Our ST Score grades it C (39.5/100). The ST Score is a data-driven signal, not a recommendation.
What are EBS's factor grades?
Valuation B, Profitability D, Financial Strength C+, Momentum D+, Growth C-, Forecast B, Sentiment F.
What is EBS's valuation grade?
Emergent BioSolutions Inc. (EBS) earns a valuation grade of B, measured against Drug Manufacturers - Specialty & Generic peers. The valuation factor looks at multiples such as P/E, P/S, P/B, EV/EBITDA and free cash flow yield.
What is EBS's growth grade?
Emergent BioSolutions Inc. (EBS) earns a growth grade of C-, measured against Drug Manufacturers - Specialty & Generic peers. The growth factor looks at revenue, earnings and cash flow growth over recent quarters and years.
What is EBS's profitability grade?
Emergent BioSolutions Inc. (EBS) earns a profitability grade of D, measured against Drug Manufacturers - Specialty & Generic peers. The profitability factor looks at margins and returns such as gross margin, net margin, ROE and ROIC.
What is EBS's financial strength grade?
Emergent BioSolutions Inc. (EBS) earns a financial strength grade of C+, measured against Drug Manufacturers - Specialty & Generic peers. The financial strength factor looks at debt levels, liquidity and coverage ratios.
What is the analyst price target for EBS?
The average analyst price target for Emergent BioSolutions Inc. (EBS) is $10.00 from 15 analysts, which is +47.7% versus the recent price of $6.77.
What is EBS's Piotroski score?
Emergent BioSolutions Inc. (EBS) has a Piotroski F-Score of 6 out of 9. The Piotroski score checks nine accounting signals covering profitability, leverage and operating efficiency; scores of 8–9 are considered strong and 0–2 weak.